VICTORIA, British Columbia–(BUSINESS WIRE)–July 26, 2022–IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), a research advanced biotherapeutics and technology company, today announced that it will host a conference call to discuss its recent financial results and business highlights for the fourth quarter and full fiscal year 2022 on Friday, July 29, 2022, at 10 a.m. 30 a.m. Eastern Time. The financial results will be published in a press release before the call.
ImmunoPrecise management will host the conference call followed by a pre-submitted question and answer period. Investors wishing to submit questions prior to the call are encouraged to email the Company’s Investor Relations contact.
When: Friday, July 29, 2022
Time: 10:30 a.m. Eastern Time
Conference ID: 9236374
Participant’s toll-free number: 1 (888) 550-5658
Participant’s toll-free number: 1 (646) 960-0289
Attendee URL: https://events.q4inc.com/attendee/831812822
The conference call will be webcast live and available for replay via a link provided in the Events section of the company’s IR pages at https://www.immunoprecise.com/investors.
Please call the conference phone number five minutes before the start time. An operator will register your name and organization.
Anyone listening to the call is encouraged to read the company’s periodic reports filed with the Toronto Stock Exchange and the Securities and Exchange Commission, including discussion of risk factors and historical operating results and condition. financial in these reports.
ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is an innovation-driven biotherapeutics company that supports its commercial partners in their quest to discover and develop novel antibodies against a wide range of target classes and diseases. The Company offers a hybrid of services and programs with advanced platforms and technologies to optimize the discovery and development of antibodies, against rare and/or difficult epitopes. For more information, visit www.immunoprecise.com.